Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07030335
Starting soon Not applicable

Evaluation of Mobile Education Program in Patients With Atrial Fibrillation.

NCT07030335 · tracked via the Priya Life Science Turkey tracker
Sponsor
Akdeniz University
Phase
Not applicable
Started
2025-06
Last updated
2025-06-22

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

Mobile-Atrial Fibrillation Training ProgramRoutine Outpatient Clinic Care

Mobile-Atrial Fibrillation Training Program: Patient Information Form, Atrial Fibrillation Information Scale, Atrial Fibrillation Severity Scale and Atrial Fibrillation Impact on Quality of Life Questionnaire will be administered face-to-face by the researcher using Mobile Atrial Fibrillation Education Program (M-AFEP). The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants and the application will be added to the main screens by entering the relevant address from their phones. Participants will be asked to use M-AFEP for twelve weeks / at least ten minutes a week and the frequency and duration of use will be recorded on the mobile application. Participants in the intervention group will be followed up by phone once a week in the first, fourth and eighth weeks and a reminder message (sms) will be sent for the use of M-AFEP. At the end of the twelfth week, the scales will be filled in again through the application.

Routine Outpatient Clinic Care: * Participants in the control group will be given M-AFEP application usage training by the researchers. * The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants in the control group. * Participants in the control group will enter the relevant address of the mobile application from their phones and the application will be added to their home screens. * In the M-AFEP application of the participants in the control group, there will be a short general information section containing information specific to AF, different from the intervention group content. Participants in the control group will continue only routine outpatient follow-up throughout the process and no intervention will be applied.

Study summary

This study was conducted to determine the effect of a mobile education program and telephone follow-up on the knowledge level, symptom management and quality of life of patients with atrial fibrillation.

The study aims to answer the following questions.

1. Does the mobile education program and telephone follow-up have an effect on increasing the level of knowledge in patients with AF in the intervention group compared to the control group?
2. Does the mobile education program and telephone follow-up have an effect on reducing symptom severity in patients with AF in the intervention group compared to the control group?
3. Does the mobile education program and telephone follow-up have an effect on improving the quality of life in patients with AF in the intervention group compared to the control group?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older. * Being literate. * Atrial Fibrillation diagnosis. * No cognitive and communication disabilities. * Not having a diagnosed psychiatric illness. * Ability to use technological devices. * Having and using a smart phone with Android operating system and internet access. * Acceptance to participate in the study. Exclusion Criteria: * Diagnosis of rheumatic valve disease, moderate/severe mitral stenosis and previous valve surgery. * Functional class III or IV according to the New York Heart Association (NYHA) classification. * Patients with existing or planned pacemaker, ICD (Implantable Cardioverter Defibrillator) and patients with existing or planned Radiofrequency Ablation treatment will not be included in the study.

Primary outcome measure(s)

  • The Jessa Atrial Fibrillation Knowledge Questionnaire — The measurement will be done at the beginning of the study (day 0) and at the end of the 12th week.
    -The Jessa Atrial Fibrillation Knowledge Questionnaire- will be used to assess participants' knowledge about their AAF condition. The scale consists of a total of 16 items and 3 sub-dimensions. The lowest score to be obtained from the scale is "0" and the highest score is "16". The higher the score obtained from the scale, the higher the patient's level of knowledge.
  • The University of Toronto Atrial Fibrillation Severity Scale — The measurement will be done at the beginning of the study (day 0) and at the end of the 12th week.
    The University of Toronto Atrial Fibrillation Severity Scale is a scale that will be used to assess the severity of AF-specific disease, the burden it creates in individuals and the frequency of AF episodes. The scale consists of 19 items and 3 sections. Higher scores indicate greater AF burden and more severe symptoms.
  • Effect of Atrial Fibrillation on Quality of Life Scale — The measurement will be done at the beginning of the study (day 0) and at the end of the 12th week.
    Effect of Atrial Fibrillation on Quality of Life Scale consists of four sub dimensions and 20 questions measuring the quality of life of patients with AF. Scoring of the scale ranges from 0 to 100 in general and sub-dimension scores. A score of zero indicates that quality of life is negatively affected.

Trial sites (1)

FacilityCityRegionStatus
Akdeniz University Hospital Cardiology Polyclinic Antalya Konyaaltı

More Akdeniz University trials in Turkey

Effect of Postoperative Holistic Nursing Care on Children's Satisfaction and Nursing Image Perception Recruiting
The Effect of Education Based on Orem's Self-Care Deficit Theory and Tele-Monitoring on Rational Drug Use in Haemodialysis Patients Enrolling by invitation
Evaluation of Salivary and Serum Levels of TNF-α, IL-17A, and YKL-40 in Individuals With Psoriasis Active, not recruiting
Three-Dimensional Scoliosis Exercises and Diaphragmatic Manual Techniques in Adolescents With Idiopathic Scoliosis Starting soon
Comfort Care Bundle Active, not recruiting

Other trials for the same condition

SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye) Enrolling by invitation
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Recruiting
PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years Enrolling by invitation
Tele-Rehabilitation After Catheter Ablation in Patients With Atrial Fibrillation Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07030335 on ClinicalTrials.gov ↗ ← All trials in Turkey